<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: EVEREST-2: A Seamless Phase 1/2 Study of A2B694, a Logic-Gated Tmod Car T-Cell Therapy, in Patients With Mesothelin-Expressing Solid Tumors With Human Leukocyte Antigen-A*02 Loss of Heterozygosity	</title>
	<atom:link href="https://www.tempus.com/publications/everest-2-a-seamless-phase-1-2-study-of-a2b694-a-logic-gated-tmod-car-t-cell-therapy-in-patients-with-mesothelin-expressing-solid-tumors-with-human-leukocyte-antigen-a02-loss-of-heterozygosity/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.tempus.com/publications/everest-2-a-seamless-phase-1-2-study-of-a2b694-a-logic-gated-tmod-car-t-cell-therapy-in-patients-with-mesothelin-expressing-solid-tumors-with-human-leukocyte-antigen-a02-loss-of-heterozygosity/</link>
	<description>AI-enabled precision medicine</description>
	<lastBuildDate>Wed, 20 Nov 2024 17:25:13 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	
</channel>
</rss>

<!--
Performance optimized by W3 Total Cache. Learn more: https://www.boldgrid.com/w3-total-cache/

Page Caching using Disk: Enhanced (Page is feed) 

Served from: www.tempus.com @ 2025-03-24 21:02:36 by W3 Total Cache
-->